Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ginsenoside Rh1 is a natural triterpenoid saponin and one of the major active constituents extracted from red ginseng (Panax ginseng). It belongs to the dammarane-type tetracyclic triterpenoids and is structurally characterized as a beta-D-glucoside of protopanaxadiol. Mechanistically, Rh1 demonstrates anti-inflammatory, antioxidant, immunomodulatory, estrogenic, neuroprotective, and cytoprotective properties primarily in vitro and in animal models. It acts through multiple targets, including modulation of inflammatory signaling, antioxidant pathways, and mitochondrial autophagy mechanisms. Rh1 has also shown positive effects on nervous system function and may support cognitive enhancement and neuroprotection through increased cell survival and upregulation of brain-derived neurotrophic factor (BDNF) in animal models. Its cytotoxicity is variable and cell-type dependent. There is currently no approved human pharmaceutical indication for ginsenoside Rh1; clinical evidence is lacking, and further investigation, particularly human trials, is recommended[1][4][7][13][15].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ginsenoside Rh1.